Quark QRK202

Status: Completed

ClinicalTrials.gov Identifier: NCT01445899

Quark QRK202: 2 part study

  • Part 1: Determines maximum tolerated dose of PF-04523655
  • Part 2: Study of PF-04523655 used alone and in combination with ranibizumab versus ranibizumab alone in patients with Diabetic Macular Edema.

Condition(s):

  • Choroidal Neovascularization
  • Diabetic Retinopathy
  • Diabetic Macular Edema

Study Type: Interventional

Duration: 2 years & 9 months

Eligibility: 

  • Ages: 18 years and older
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information on this study, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.